Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
Prophylactic aprotinin therapy has become a popular method to reduce bleeding associated with cardiac operations. Today essentially two dose regimens are used, a high-dose regimen with administration throughout the complete operative procedure and a low-dose regimen with administration only during bypass. In unblinded studies both regimens were found to be equally effective. This double-blind placebo-controlled study in 115 patients undergoing elective coronary artery bypass grafting was done to confirm these results without potential investigator bias. Intraoperative hemoglobin loss was significantly reduced (p < 0.01) by 42% in the high-dose group and by 17% in the low-dose group compared with loss in control subjects. Blood loss 6 hours after operation was 377 ml in the low-dose and 266 ml in the high-dose group compared with 630 ml in the placebo group (p < 0.05 and p < 0.001, respectively). The average number of transfusions with packed red blood cells was reduced 31% in the low-dose group and 45% in the high-dose group, but the reductions were not significant. In a subgroup of patients, markers for coagulation and fibrinolysis were studied to investigate whether a different extent of activation existed. Fibrinolysis as measured by D-dimer levels was completely inhibited by the high-dose regimen, but was only partly suppressed in the low-dose group as compared with findings in the placebo group. Thrombin generation during cardiopulmonary bypass as reflected by F1 + 2 levels was lower in patients treated with aprotinin, but the difference was not significant. Concentrations of thrombin inactivated by antithrombin III were not different between the groups. The observation that low-dose aprotinin significantly improved hemostasis but did not inhibit hyperfibrinolysis supports our previous finding that low-dose aprotinin mainly protects platelet adhesive function. The better result obtained with high-dose aprotinin may indicate the contribution of hyperfibrinolysis to bleeding after cardiopulmonary bypass. Because high-dose aprotinin is administered outside the period of full heparinization and might therefore increase the risk of thromboembolic complications, we propose a modification of the low-dose schedule to increase aprotinin levels sufficient for plasmin inhibition before release of the aortic crossclamp.
Speekenbrink
R G
RG
Department of Thoracic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Wildevuur
C R
CR
Sturk
A
A
Eijsman
L
L
D000990:Antithrombin III / Q000032:analysis; D007611:Aprotinin / Q000008:administration & dosage*; D015982:Bias; D001777:Blood Coagulation; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D017558:Elective Surgical Procedures; D017707:Erythrocyte Transfusion; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000037:antagonists & inhibitors; D005342:Fibrinolysis; D006454:Hemoglobins / Q000032:analysis; D006488:Hemostasis, Surgical; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013917:Thrombin / Q000032:analysis / Q000037:antagonists & inhibitors
D005338:Fibrin Fibrinogen Degradation Products; D006454:Hemoglobins; D006490:Hemostatics; D010919:Placebos; C036309:fibrin fragment D; D000990:Antithrombin III; D007611:Aprotinin; D013917:Thrombin; D005341:Fibrinolysin